Sanford R Simon

US Patent:

7091396, Aug 15, 2006

Filed:

Oct 17, 2001

Appl. No.:

09/982120

Inventors:

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

Assignee:

The Rockefeller University - New York NY

International Classification:

A01K 67/027
A01K 67/033
C12N 15/63
C12N 5/06
C12N 5/10

US Classification:

800 18, 800 13, 435326, 435325, 435455, 4353201

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

20020042079, Apr 11, 2002

Filed:

May 18, 1998

Appl. No.:

09/080739

Inventors:

SANFORD M. SIMON - NEW YORK NY, US
MELVIN S. SCHINDLER - OKEMOS MI, US

International Classification:

A01N001/02
C12Q001/00
G01N033/53
G01N033/567
G01N033/574
C12Q001/02
G01N031/16
G01N031/22
G01N021/76
C12N005/00
C12N005/02
C12N005/08

US Classification:

435/007100, 435/002000, 435/004000, 435/029000, 435/007800, 435/007210, 435/325000, 435/366000, 435/374000, 436/163000, 436/172000

Abstract:

The effect of the pH of intracellular vesicular compartments and intracellular vesicular transport on multidrug resistance (MDR) of tumor cells is examined. The invention comprises in one aspect the treatment of MDR by administering a therapeutically effective amount of a pH modulator and/or a compound that can interfere with the vesicular transport of an intracellular vesicular compartment. Diagnostic utilities are contemplated and extend to drug discovery assays and methods for measuring monitoring the status of the onset or development of MDR, as well as the measurement of intracellular drug accumulation. Therapeutic compositions include a composition comprising a pH modulator alone or in combination with the dose-limited therapeutic agent(s), and a pharmaceutically acceptable excipient, are also contemplated.

US Patent:

20030049597, Mar 13, 2003

Filed:

Mar 1, 2001

Appl. No.:

09/797496

Inventors:

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

C12Q001/00
C12Q001/37
C12N015/87

US Classification:

435/004000, 435/023000, 435/455000

Abstract:

Method for similtaneously quantifying in situ the relationship between an enzyme and its substrate, especially by the use of fluorescence.

US Patent:

20060288430, Dec 21, 2006

Filed:

Jun 23, 2006

Appl. No.:

11/474133

Inventors:

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

A01K 67/027

US Classification:

800006000, 800014000

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

20090193530, Jul 30, 2009

Filed:

Dec 12, 2008

Appl. No.:

12/316433

Inventors:

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

A01K 67/027
C12N 15/85
C12N 5/06
C07K 16/18

US Classification:

800 6, 800 14, 435328, 5303917

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

20130064762, Mar 14, 2013

Filed:

Sep 12, 2012

Appl. No.:

13/611599

Inventors:

Sanford M. Simon - New York NY, US

Assignee:

The Rockefeller University - New York NY

International Classification:

G01N 33/574
G01N 21/64
A61K 49/16
A61K 49/00
A61K 51/10

US Classification:

424 149, 424 91, 435 71, 424 934

Abstract:

This invention generally relates to a method of identifying pre-neoplastic or neoplastic tissue of a mammal by utilizing autoantibodies that detect the pre-neoplastic or neoplastic tissue. Also described herein are methods of killing pre-neoplastic or neoplastic tissue by either binding toxins to autoantibodies that detect the pre-neoplastic or neoplastic tissue or introducing toxin-conjugated molecules that can in turn recognize the autoantibodies already bound to the pre-neoplastic or neoplastic tissue.

US Patent:

58517898, Dec 22, 1998

Filed:

Sep 29, 1995

Appl. No.:

8/535995

Inventors:

Sanford M. Simon - New York NY
Melvin M. S. Schindler - Okemos MI

Assignee:

The Rockefeller University - New York NY
Board of Trustees Operating Michigan State University - East Lansing MI

International Classification:

C12Q 118
C12Q 102
G01N 2180
G01N 3100

US Classification:

435 32

Abstract:

The predominant effect of pH change on multidrug resistance (MDR) independent of active drug efflux has been demonstrated in tumor cells through studies of the drugs doxorubicin and daunomycin. Specifically, the distribution of both drugs was monitored in fibroblasts and myeloma cells to examine the role of pH in drug partitioning. The invention comprises in one aspect the treatment of MDR by administering a therapeutically effective amount of a pH modulator. Diagnostic utilities are contemplated and extend to drug discovery assays and methods for measuring monitoring the status of the onset or development of pH-related conditions such as MDR, as well as the measurement of intracellular drug accumulation. Therapeutic compositions include a composition comprising a pH modulator alone or in combination with the dose-limited therapeutic agent(s), and a pharmaceutically acceptable excipient, are also contemplated.

US Patent:

51283182, Jul 7, 1992

Filed:

Oct 27, 1988

Appl. No.:

7/263543

Inventors:

Daniel M. Levine - New York NY
Sanford R. Simon - Selden NY
Bruce R. Gordon - New York NY
Thomas S. Parker - Brooklyn NY
Stuart D. Saal - New York NY
Albert L. Rubin - Englewood NJ

Assignee:

The Rogosin Institute - New York NY

International Classification:

A61K 3702

US Classification:

514 2

Abstract:

A reconstituted high density lipoprotein containing particle is disclosed. The particle is useful in removing excess lipid soluble material from a subject to which it is administered, as well as in delivery of lipid soluble pharmaceuticals to subjects or patients.